Jonathan M Hill1, Dean J Kereiakes2, Richard A Shlofmitz3, Andrew J Klein4, Robert F Riley5, Matthew J Price6, Howard C Herrmann7, William Bachinsky8, Ron Waksman9, Gregg W Stone10. 1. Department of Cardiology, Royal Brompton Hospital, London, United Kingdom. Electronic address: https://twitter.com/DrJMHill. 2. The Christ Hospital and Lindner Research Center, Cincinnati, Ohio. Electronic address: Dean.Kereiakes@thechristhospital.com. 3. The Heart Center, St. Francis Hospital, Roslyn, New York. 4. Piedmont Heart Interventional Cardiology, Atlanta, Georgia. 5. The Christ Hospital and Lindner Research Center, Cincinnati, Ohio. 6. Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, California. Electronic address: https://twitter.com/matthewjpricemd. 7. Cardiac Catheterizaton Laboratories, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania. 8. Heart & Vascular Institute, UPMC Pinnacle Health, Harrisburg, Pennsylvania. Electronic address: https://twitter.com/Billbachinskymd. 9. Division of Cardiology, MedStar Cardiovascular Research Network, MedStar Washington Hospital Center, Washington, DC. 10. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: https://twitter.com/GreggWStone.
Abstract
BACKGROUND: Coronary calcification hinders stent delivery and expansion and is associated with adverse outcomes. Intravascular lithotripsy (IVL) delivers acoustic pressure waves to modify calcium, enhancing vessel compliance and optimizing stent deployment. OBJECTIVES: The purpose of this study was to assess the safety and effectiveness of IVL in severely calcified de novo coronary lesions. METHODS: Disrupt CAD III (NCT03595176) was a prospective, single-arm multicenter study designed for regulatory approval of coronary IVL. The primary safety endpoint was freedom from major adverse cardiovascular events (cardiac death, myocardial infarction, or target vessel revascularization) at 30 days. The primary effectiveness endpoint was procedural success. Both endpoints were compared with a pre-specified performance goal (PG). The mechanism of calcium modification was assessed in an optical coherence tomography (OCT) substudy. RESULTS: Patients (n = 431) were enrolled at 47 sites in 4 countries. The primary safety endpoint of the 30-day freedom from major adverse cardiovascular events was 92.2%; the lower bound of the 95% confidence interval was 89.9%, which exceeded the PG of 84.4% (p < 0.0001). The primary effectiveness endpoint of procedural success was 92.4%; the lower bound of the 95% confidence interval was 90.2%, which exceeded the PG of 83.4% (p < 0.0001). Mean calcified segment length was 47.9 ± 18.8 mm, calcium angle was 292.5 ± 76.5°, and calcium thickness was 0.96 ± 0.25 mm at the site of maximum calcification. OCT demonstrated multiplane and longitudinal calcium fractures after IVL in 67.4% of lesions. Minimum stent area was 6.5 ± 2.1 mm2 and was similar regardless of demonstrable fractures on OCT. CONCLUSIONS: Coronary IVL safely and effectively facilitated stent implantation in severely calcified lesions.
BACKGROUND:Coronary calcification hinders stent delivery and expansion and is associated with adverse outcomes. Intravascular lithotripsy (IVL) delivers acoustic pressure waves to modify calcium, enhancing vessel compliance and optimizing stent deployment. OBJECTIVES: The purpose of this study was to assess the safety and effectiveness of IVL in severely calcified de novo coronary lesions. METHODS: Disrupt CAD III (NCT03595176) was a prospective, single-arm multicenter study designed for regulatory approval of coronary IVL. The primary safety endpoint was freedom from major adverse cardiovascular events (cardiac death, myocardial infarction, or target vessel revascularization) at 30 days. The primary effectiveness endpoint was procedural success. Both endpoints were compared with a pre-specified performance goal (PG). The mechanism of calcium modification was assessed in an optical coherence tomography (OCT) substudy. RESULTS:Patients (n = 431) were enrolled at 47 sites in 4 countries. The primary safety endpoint of the 30-day freedom from major adverse cardiovascular events was 92.2%; the lower bound of the 95% confidence interval was 89.9%, which exceeded the PG of 84.4% (p < 0.0001). The primary effectiveness endpoint of procedural success was 92.4%; the lower bound of the 95% confidence interval was 90.2%, which exceeded the PG of 83.4% (p < 0.0001). Mean calcified segment length was 47.9 ± 18.8 mm, calcium angle was 292.5 ± 76.5°, and calcium thickness was 0.96 ± 0.25 mm at the site of maximum calcification. OCT demonstrated multiplane and longitudinal calciumfractures after IVL in 67.4% of lesions. Minimum stent area was 6.5 ± 2.1 mm2 and was similar regardless of demonstrable fractures on OCT. CONCLUSIONS: Coronary IVL safely and effectively facilitated stent implantation in severely calcified lesions.
Authors: Keyvan Karimi Galougahi; Evan Shlofmitz; Allen Jeremias; Shawnbir Gogia; Ajay J Kirtane; Jonathan M Hill; Dimitri Karmpaliotis; Gary S Mintz; Akiko Maehara; Gregg W Stone; Richard A Shlofmitz; Ziad A Ali Journal: Curr Cardiol Rep Date: 2021-03-05 Impact factor: 2.931
Authors: Anthony J Buckley; John P McCormick; James Carey; Richard Armstrong; Andrew Maree; Mark Hensey; Stephen O'Connor; Ross Murphy; Caroline Daly; John Cosgrave; Ian Pearson Journal: Ir J Med Sci Date: 2022-07-09 Impact factor: 1.568
Authors: Ata Doost; James Marangou; Thato Mabote; Gerald Yong; Sharad Shetty; Alan Whelan; Matthew Erickson; Michael Nguyen; Christopher Judkins; Anthony Putrino; Abdul Rahman Ihdayhid; Richard Clugston; James Rankin Journal: AsiaIntervention Date: 2022-03-15
Authors: Himanshu Rai; Fiona Harzer; Tatsuhiko Otsuka; Youssef S Abdelwahed; Paula Antuña; Florian Blachutzik; Tobias Koppara; Lorenz Räber; David M Leistner; Fernando Alfonso; Holger Nef; Masaru Seguchi; Alp Aytekin; Erion Xhepa; Sebastian Kufner; Salvatore Cassese; Karl-Ludwig Laugwitz; Robert A Byrne; Adnan Kastrati; Michael Joner Journal: J Am Heart Assoc Date: 2022-04-26 Impact factor: 6.106
Authors: Giorgio A Medranda; Brian C Case; Jason P Wermers; Natalie Morrison; Charan Yerasi; Brian Forrestal; Chava Chezar-Azerrad; Ron Waksman Journal: Cardiovasc Revasc Med Date: 2021-01-04
Authors: Bachir Abdulrahman; Kambis Mashayekhi; Péter Tajti; Miroslaw Ferenc; Christian Marc Valina; Willibald Hochholzer; Franz-Josef Neumann; Thomas Georg Nührenberg Journal: J Clin Med Date: 2020-12-07 Impact factor: 4.241